Efficacy and Safety of Melphalan, Cyclophosphamide and Dexamethasone (MCD) as a Salvage Treatment for Patients with Relapsed/Refractory Multiple Myeloma / 전남의대학술지
Chonnam Medical Journal
;
: 25-30, 2019.
Article
in English
| WPRIM
| ID: wpr-719479
ABSTRACT
This study investigated the efficacy and safety of melphalan, cyclophosphamide, and dexamethasone (MCD) as a salvage regimen for heavily treated relapsed or refractory multiple myeloma patients. We retrospectively analyzed a total of 27 patients who received the MCD regimen between April 2011 and November 2013. The MCD regimen consisted of oral melphalan 6.75 mg/m² on days 1–4, once-weekly dose of oral cyclophosphamide 300 mg/m2 and dexamethasone 20 mg/m² on days 1–4 and days 15–18. Each cycle was repeated every 28 days. The median age of the patients was 66 years and the MCD regimen was initiated at a median 37.7 months from diagnosis. Patients received a median of five regimens including autologous stem cell transplantation. The overall response rate was 25.9% (very good partial response 3.7%, partial response 22.2%) and 8 (29.6%) patients achieved a minor response. Median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2–8.5) ; overall survival 11.7 months (95% CI, 5.4–16.6). Grade 3 or 4 neutropenia and thrombocytopenia were observed in 51.8% and 33.3%, respectively. Although the overall response rate is relatively low, the MCD regimen may have a role as a bridge to a novel regimen in heavily pretreated patients with MM.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thrombocytopenia
/
Dexamethasone
/
Retrospective Studies
/
Salvage Therapy
/
Disease-Free Survival
/
Cyclophosphamide
/
Stem Cell Transplantation
/
Diagnosis
/
Melphalan
/
Multiple Myeloma
Type of study:
Diagnostic study
/
Observational study
Limits:
Humans
Language:
English
Journal:
Chonnam Medical Journal
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS